SARS-CoV-2 Spike and Nucleocapsid Antibody Response in Vaccinated Croatian Healthcare Workers and Infected Hospitalized Patients: A Single Center Cohort Study
Authors:
- Paola Kučan BrlićPaola Kučan Brlić
- Martina PavletićMPMartina Pavletić
- Mate LergaMLMate Lerga
- Fran KrstanovićFKFran Krstanović
- Marina Pribanić MatešićMMMarina Pribanić Matešić
- Karmela MiklićKMKarmela Miklić
- Suzana MalićSMSuzana Malić
- Leonarda MikšaLMLeonarda Mikša
- Maja PajcurMPMaja Pajcur
- Dolores PeručDPDolores Peruč
- Maren SchubertMSMaren Schubert
- Federico BertoglioFBFederico Bertoglio
Open Access
Abstract
Studies assessing the dynamics and duration of antibody responses following SARS-CoV-2 infection or vaccination are an invaluable tool for vaccination schedule planning, assessment of risk groups and management of pandemics. In this study, we developed and employed ELISA assays to analyze the humoral responses to Nucleocapsid and Spike proteins in vaccinated health-care workers (HCW) and critically ill COVID-19 patients. Sera of more than 1000 HCWs and critically ill patients from the Clinical Hospital Center Rijeka were tested across a one-year period, encompassing the spread of major SARS-CoV-2 variants of concern (VOCs). We observed 97% of seroconversion in HCW cohort as well as sustained anti-Spike antibody response in vaccinees for more than 6 months. In contrast, the infection-induced anti-Nucleocapsid response was waning significantly in a six-month period. Furthermore, a substantial decrease in vaccinees’ anti-Spike antibodies binding to Spike protein of Omicron VOC was also observed. Critically ill COVID-19 patients had higher levels of anti-Spike and anti-Nucleocapsid antibodies compared to HCWs. No significant differences in anti-Spike and anti-Nucleocapsid antibody levels between the critically ill COVID-19 patients that were on non-invasive oxygen supplementation and those on invasive ventilation support were observed. However, stronger anti-Spike, but not anti-Nucleocapsid, antibody response correlated with a better disease outcome in the cohort of patients on invasive ventilation support. Altogether, our results contribute to the growing pool of data on humoral responses to SARS-CoV-2 infection and vaccination.Keywords
Funding Information
- Hrvatska Zaklada za Znanost (IPCORONA-04-2073)
- European Regional Development Fund (KK.01.1.1.01.0006)
- Scientific Centre of Excellence for Virus Immunology and Vaccines
- European Regional Development Fund
- Helmholtz-Gemeinschaft (PIE-0008)
This publication has 99 references indexed in Scilit:
- Monitoring antibody response following SARS-CoV-2 infection: diagnostic efficiency of 4 automated immunoassaysDiagnostic Microbiology and Infectious Disease, 2020
- Clinical and immunological assessment of asymptomatic SARS-CoV-2 infectionsNature Medicine, 2020
- Dissecting antibody-mediated protection against SARS-CoV-2Nature Reviews Immunology, 2020
- Sensitivity in Detection of Antibodies to Nucleocapsid and Spike Proteins of Severe Acute Respiratory Syndrome Coronavirus 2 in Patients With Coronavirus Disease 2019The Journal of Infectious Diseases, 2020
- SARS‐CoV‐2 Seroconversion in Humans: A Detailed Protocol for a Serological Assay, Antigen Production, and Test SetupCurrent Protocols in Microbiology, 2020
- A pneumonia outbreak associated with a new coronavirus of probable bat originNature, 2020
- Cytomegalovirus Seroprevalence and Birth Prevalence of Congenital CMV Infection in Bosnia and HerzegovinaThe Pediatric Infectious Disease Journal, 2020
- An ELISA protocol to improve the accuracy and reliability of serological antibody assaysMethodsX, 2017
- Preventing intense false positive and negative reactions attributed to the principle of ELISA to re-investigate antibody studies in autoimmune diseasesJournal of Immunological Methods, 2014
- Washing of ELISA plates with running tap waterJournal of Immunological Methods, 1986